# The biotechnology company on Thursday reported a first-quarter profit of $1.82 billion.

*biotech · news · 2026-04-30 · MarketScreener*

## Key points

- Amgen's adjusted earnings per share beat analyst expectations by $0.38 in the first quarter.
- Sixteen Amgen products achieved double-digit sales growth during the first quarter.
- The FDA has proposed withdrawing approval for Amgen's Tavneos due to concerns over effectiveness.
- Serious liver injuries, including eight deaths, have been linked to Amgen's Tavneos drug.

**Companies:** Amgen
**Countries:** United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/amgen-posts-higher-1q-profit-revenue-ce7f58d8dc80f52d)

---

Canonical: https://newsio.io/n/02dcc48a-3978-4712-bd1a-99b684ed3963/the-biotechnology-company-on-thursday-reported-a-first-quarter-profit-of-1-82-bi
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works